Drug

Cevostamab clinical trials

Also written RO7187797.

studies test it: 10
open now: 5
in phase 3: 1
first study started: 2017

How each study uses cevostamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the cevostamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cevostamab: 10

Development codes

RO7187797: 3
BFCR4350A: 1

Studies by the year they started

10 studies that test it; most in 2026 (4)

Studies that test cevostamab, by start year
Year	Studies
2017	1
2021	1
2022	1
2023	2
2025	1
2026	4

By phase

A phase 1/2 study counts in both.

Phase 1: 7
Phase 2: 3
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Multiple Myeloma: 9
Lupus Erythematosus, Systemic: 1

Who runs them

Industry 8 · Other 2

Genentech, Inc. (4) · Hoffmann-La Roche (4) · University of Pennsylvania (1) · Canadian Myeloma Research Group (1)

Often tested with

Tested in the same studies.

Belantamab mafodotin (1) · Dexamethasone (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test cevostamab.

Nov 2026A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple MyelomaPhase 1 · Genentech, Inc.
Feb 2027A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple MyelomaPhase 1/2 · Hoffmann-La Roche
May 2027Cevostamab Following CAR T Cell Therapy for RRMMPhase 2 · University of Pennsylvania

Studies

Open first, then newest update. How each study uses cevostamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 10

Given beside what is tested · 4 — cevostamab is usual care or a partner of the new treatment

Codes

What other systems call cevostamab · ClinicalTrials.gg INT017557

UNII (FDA) P86BHN01VECEVOSTAMABConfirmed FDA, Wikidata
Wikidata Q136090403cevostamabConfirmed FDA, Wikidata
NCI Thesaurus C139549CevostamabOne source FDA
DrugBank DB18374One source Wikidata

System	Code	Name there	Checked by
UNII (FDA)	P86BHN01VE	CEVOSTAMAB	Confirmed FDA, Wikidata
Wikidata	Q136090403	cevostamab	Confirmed FDA, Wikidata
NCI Thesaurus	C139549	Cevostamab	One source FDA
DrugBank	DB18374	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.